While agents such as anti-VEGF antibodies and tyrosine kinase inhibitors have shown promise in several malignancies [29], their efficacy in PCa has been inconsistent, possibly due to the disease’s molecular heterogeneity [30]. This evidence concerns the gene VEGFA and posterior cortical atrophy.